To study the role of short term teriparatide injection in the management of intertrochanteric fracture of hip in elderly patients after osteosynthesis

Abstract

Introduction: Osteoporosis negatively affects the patients quality of life and results in high Healthcare cost. Teriparatide is a synthetic polypeptide hormone that contains 1-34 amino acid fragment of the recombinant human parathyroid hormone and it is claimed to fasten fracture healing. Hence we decided to carry out a study to find out the effect of teriparatide injection if given for short term, in elderly osteoporotic intertrochanteric fractures, in the postoperative period.Materials and Methods: We carried out non randomised, controlled non inferiority clinical trial at MIMER medical college talegaon dabhade from 1st august 2018 to 31st July 2019. We enrolled patients into two groups. Group A received injection teriparatide 20 microgram daily with 400 IU of Vitamin D3 and 1200 milligram calcium for 3 months in the post-operative period. Group B received only 400 IU of Vitamin D3 and 1200 milligram of calcium for 3 months. We followed up patients at 6 weeks, 12 weeks, 24 weeks, 36 weeks for pain at fracture site, radiological sign of union.Results: Results of our study showed that Union time in group A(patients who received teriparatide) was significantly less than group B. Harris hip score was also significantly better in group A as compared to group B.Conclusion: In this prospective, non randomised controlled, non-inferiority clinical trial 3 months of injection teriparatide after surgery was associated with significantly shorter time for fracture union, better functional outcome and no complications.